J Kevin Buchi - Net Worth and Insider Trading
J Kevin Buchi Net Worth
The estimated net worth of J Kevin Buchi is at least $646,913 dollars as of 2024-05-13. J Kevin Buchi is the Director of Benitec Biopharma Inc and owns about 52,097 shares of Benitec Biopharma Inc (BNTC) stock worth over $481,897. J Kevin Buchi is the Director of Stemline Therapeutics Inc and owns about 13,772 shares of Stemline Therapeutics Inc (STML) stock worth over $162,923. J Kevin Buchi is also the Director of Ampio Pharmaceuticals Inc and owns about 7,343 shares of Ampio Pharmaceuticals Inc (AMPE) stock worth over $2,093. Details can be seen in J Kevin Buchi's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that J Kevin Buchi has not made any transactions after 2023-08-11 and currently still holds the listed stock(s).
Transaction Summary of J Kevin Buchi
J Kevin Buchi Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, J Kevin Buchi owns 10 companies in total, including Alaunos Therapeutics Inc (TCRT) , Dicerna Pharmaceuticals Inc (DRNA) , and Amneal Pharmaceuticals Inc (AMRX) among others .
Click here to see the complete history of J Kevin Buchi’s form 4 insider trades.
Insider Ownership Summary of J Kevin Buchi
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
TCRT | Alaunos Therapeutics Inc | 2020-09-21 | director |
DRNA | Dicerna Pharmaceuticals Inc | 2020-06-15 | director |
AMRX | Amneal Pharmaceuticals Inc | 2018-05-04 | director |
2023-08-11 | director | ||
2019-10-23 | director & Chief Executive Officer | ||
2016-06-21 | director | ||
2015-06-23 | director | ||
2015-06-05 | director | ||
2015-03-26 | director & President & CEO | ||
2023-06-09 | director |
J Kevin Buchi Latest Holdings Summary
J Kevin Buchi currently owns a total of 3 stocks. Among these stocks, J Kevin Buchi owns 52,097 shares of Benitec Biopharma Inc (BNTC) as of August 11, 2023, with a value of $481,897 and a weighting of 74.49%. J Kevin Buchi owns 13,772 shares of Stemline Therapeutics Inc (STML) as of January 29, 2013, with a value of $162,923 and a weighting of 25.18%. J Kevin Buchi also owns 7,343 shares of Ampio Pharmaceuticals Inc (AMPE) as of June 9, 2023, with a value of $2,093 and a weighting of 0.32%.
Latest Holdings of J Kevin Buchi
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
BNTC | Benitec Biopharma Inc | 2023-08-11 | 52,097 | 9.25 | 481,897 |
STML | Stemline Therapeutics Inc | 2013-01-29 | 13,772 | 11.83 | 162,923 |
AMPE | Ampio Pharmaceuticals Inc | 2023-06-09 | 7,343 | 0.29 | 2,093 |
Holding Weightings of J Kevin Buchi
J Kevin Buchi Form 4 Trading Tracker
According to the SEC Form 4 filings, J Kevin Buchi has made a total of 1 transactions in Benitec Biopharma Inc (BNTC) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Benitec Biopharma Inc is the acquisition of 51,813 shares on August 11, 2023, which cost J Kevin Buchi around $145,595.
According to the SEC Form 4 filings, J Kevin Buchi has made a total of 0 transactions in Stemline Therapeutics Inc (STML) over the past 5 years. The most-recent trade in Stemline Therapeutics Inc is the acquisition of 500 shares on January 29, 2013, which cost J Kevin Buchi around $5,000.
According to the SEC Form 4 filings, J Kevin Buchi has made a total of 4 transactions in Ampio Pharmaceuticals Inc (AMPE) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Ampio Pharmaceuticals Inc is the acquisition of 1,093 shares on June 9, 2023, which cost J Kevin Buchi around $6,339.
Insider Trading History of J Kevin Buchi
- 1
J Kevin Buchi Trading Performance
GuruFocus tracks the stock performance after each of J Kevin Buchi's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by J Kevin Buchi is -9.26%. GuruFocus also compares J Kevin Buchi's trading performance to market benchmark return within the same time period. The performance of stocks bought by J Kevin Buchi within 3 months outperforms 2 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how J Kevin Buchi's insider trading performs compared to the benchmark.
Performance of J Kevin Buchi
J Kevin Buchi Ownership Network
Ownership Network List of J Kevin Buchi
Ownership Network Relation of J Kevin Buchi
J Kevin Buchi Owned Company Details
What does Alaunos Therapeutics Inc do?
Who are the key executives at Alaunos Therapeutics Inc?
J Kevin Buchi is the director of Alaunos Therapeutics Inc. Other key executives at Alaunos Therapeutics Inc include director & Chief Executive Officer Boyle Kevin S. Sr. , VP & Finance Michael Wong , and See Remarks Abhishek K Srivastava .
Alaunos Therapeutics Inc (TCRT) Insider Trades Summary
Over the past 18 months, J Kevin Buchi made no insider transaction in Alaunos Therapeutics Inc (TCRT). Other recent insider transactions involving Alaunos Therapeutics Inc (TCRT) include a net purchase of 1,250,000 shares made by Jaime Vieser , a net purchase of 750,000 shares made by Robert W Postma , and a net sale of 68,014 shares made by Boyle Kevin S. Sr. .
In summary, during the past 3 months, insiders sold 0 shares of Alaunos Therapeutics Inc (TCRT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 4,534 shares of Alaunos Therapeutics Inc (TCRT) were sold and 133,333 shares were bought by its insiders, resulting in a net purchase of 128,799 shares.
Alaunos Therapeutics Inc (TCRT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Alaunos Therapeutics Inc Insider Transactions
J Kevin Buchi Mailing Address
Above is the net worth, insider trading, and ownership report for J Kevin Buchi. You might contact J Kevin Buchi via mailing address: 41 Moores Road, Frazer Pa 19355.